1-[6,6-dimethyl-4-[(5-propan-2-yl-1H-pyrazol-3-yl)amino]-5,7-dihydrocyclopenta[d]pyrimidin-2-yl]-1-(6-fluoropyridin-3-yl)pyrrolidin-1-ium-2-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-[6,6-dimethyl-4-[(5-propan-2-yl-1H-pyrazol-3-yl)amino]-5,7-dihydrocyclopenta[d]pyrimidin-2-yl]-1-(6-fluoropyridin-3-yl)pyrrolidin-1-ium-2-carboxamide
• 化学式: C25H32FN8O+
• 分子量: 479.6
• InChiKey: YQWGROSXTMSZDH-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  123
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS PYRIMIDINE FUSIONNÉS ET LEUR UTILISATION
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2014105958A2

  公开（公告）日：2014-07-03

  Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.